DCT Advisors Approve $22 Mil. Set Aside For Interactive R01s Systemic Therapies
In Brief: NCI Awards 4 Contracts For Enrichment Program; Dana-Farber Names Breast Center Leadership
NIH Authorization Set For Another Try; Women’s Cancers Are Targeted
DCT Advisers Ok Expansion of Phase 1, Phase 2 Testing
More DCT Concepts Approved By Advisors
Taxotere Encouraging, CPT-11, Other Agents Entering Trials; Chabner
Procedures For Ending IGs Announced
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Anthony Letai pledges to ensure stability for extramural and intramural cancer science









